Biogen, Sangamo collaborate for gene regulation therapies in neurological ailments Medical Dialogues Bureau10 March 2020 3:30 AM GMTBiogen has exclusive global rights to ST-501 for tauopathies including Alzheimer's disease, ST-502 for synucleinopathies including Parkinson's...